After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Could a new ADC project distract attention away from evorpacept?
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
